CN114040914A - 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 - Google Patents

喹唑啉酮类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
CN114040914A
CN114040914A CN202080045383.8A CN202080045383A CN114040914A CN 114040914 A CN114040914 A CN 114040914A CN 202080045383 A CN202080045383 A CN 202080045383A CN 114040914 A CN114040914 A CN 114040914A
Authority
CN
China
Prior art keywords
compound
groups
atropisomer
mixture
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080045383.8A
Other languages
English (en)
Inventor
陆标
桂斌
沈晓冬
王玉明
贺峰
白昌
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN114040914A publication Critical patent/CN114040914A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种通式(I)所示的喹唑啉酮类衍生物，其制备方法，含有该衍生物的药物组合物，以及该衍生物作为治疗剂，特别是作为KRAS抑制剂的用途。

Description

PCT国内申请，说明书已公开。

Claims (32)

  1. PCT国内申请，权利要求书已公开。
CN202080045383.8A 2019-07-01 2020-07-01 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 Pending CN114040914A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2019105849474 2019-07-01
CN201910584947 2019-07-01
CN2020100743353 2020-01-22
CN202010074335 2020-01-22
CN2020102778874 2020-04-10
CN202010277887 2020-04-10
CN202010362869 2020-04-30
CN2020103628696 2020-04-30
PCT/CN2020/099690 WO2021000885A1 (zh) 2019-07-01 2020-07-01 喹唑啉酮类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
CN114040914A true CN114040914A (zh) 2022-02-11

Family

ID=74100226

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080045383.8A Pending CN114040914A (zh) 2019-07-01 2020-07-01 喹唑啉酮类衍生物、其制备方法及其在医药上的应用

Country Status (3)

Country Link
CN (1) CN114040914A (zh)
TW (1) TW202115089A (zh)
WO (1) WO2021000885A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390818A (zh) * 2019-08-12 2021-02-23 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
WO2020085493A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 新規なインダゾール化合物又はその塩
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP4021444A4 (en) 2019-08-29 2023-01-04 Mirati Therapeutics, Inc. G12D KRAS INHIBITORS
CA3152025A1 (en) 2019-09-24 2021-04-01 David BRIERE Combination therapies
JP7340100B2 (ja) 2019-10-28 2023-09-06 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬
CN115135315A (zh) 2019-12-20 2022-09-30 米拉蒂治疗股份有限公司 Sos1抑制剂
CN113980032B (zh) * 2020-07-27 2023-06-16 江苏恒瑞医药股份有限公司 稠合四环类衍生物、其制备方法及其在医药上的应用
AU2022280025A1 (en) * 2021-05-25 2023-12-07 Erasca, Inc. Sulfur-containing heteroaromatic tricyclic kras inhibitors
KR20240024903A (ko) 2021-06-21 2024-02-26 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 융합된 사환식 화합물, 이에 대한 제조 방법 및 의학에서 이의 적용
AU2022314009A1 (en) * 2021-07-23 2024-01-25 Suzhou Zanrong Pharma Limited Kras g12d inhibitors and uses thereof
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
TW202322819A (zh) * 2021-10-22 2023-06-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮的四環化合物、其製備方法及其在醫藥上的應用
WO2024022471A1 (zh) * 2022-07-28 2024-02-01 上海湃隆生物科技有限公司 Kras抑制剂化合物
WO2024031088A1 (en) 2022-08-05 2024-02-08 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
WO2024104453A1 (zh) * 2022-11-17 2024-05-23 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
WO2018217651A1 (en) * 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
CN113767106A (zh) * 2019-04-28 2021-12-07 劲方医药科技(上海)有限公司 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180005178A (ko) * 2015-04-10 2018-01-15 아락세스 파마 엘엘씨 치환된 퀴나졸린 화합물 및 이의 사용방법
EA038635B9 (ru) * 2015-11-16 2021-10-26 Араксис Фарма Ллк 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
WO2017201161A1 (en) * 2016-05-18 2017-11-23 Mirati Therapeutics, Inc. Kras g12c inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
WO2018217651A1 (en) * 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
CN113767106A (zh) * 2019-04-28 2021-12-07 劲方医药科技(上海)有限公司 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390818A (zh) * 2019-08-12 2021-02-23 劲方医药科技(上海)有限公司 取代的杂芳环并二氢嘧啶酮衍生物，其制法与医药上的用途

Also Published As

Publication number Publication date
WO2021000885A1 (zh) 2021-01-07
TW202115089A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
CN114040914A (zh) 喹唑啉酮类衍生物、其制备方法及其在医药上的应用
CN109890797B (zh) 可用作抗癌剂的取代的碳核苷衍生物
CN110511209B (zh) 可用作激酶抑制剂的吲哚甲酰胺化合物
CN109219604B (zh) 四氢异喹啉雌激素受体调节剂及其用途
CN114728968A (zh) 稠合吡啶酮类化合物及其制备方法和应用
CN107253963B (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法
CN113508118A (zh) 用作抗癌剂的稠合三环化合物
TW202110837A (zh) 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用
WO2022268051A1 (zh) 稠合四环类化合物、其制备方法及其在医药上的应用
JP2017518276A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
TWI623316B (zh) Antitumor effect enhancer derived from pyrrolopyrimidine compound
CN104540830A (zh) 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂
CN113801114A (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
KR101947289B1 (ko) 신규 피롤로피리미딘 화합물 또는 그의 염, 및 이것을 함유하는 의약 조성물, 특히 nae 저해 작용에 기초하는 종양 등의 예방제 및/또는 치료제
CN113980032B (zh) 稠合四环类衍生物、其制备方法及其在医药上的应用
WO2021208918A1 (zh) 作为egfr抑制剂的三环化合物
WO2022037560A1 (zh) 嘧啶酮衍生物及其在药物中的应用
CN115867346A (zh) 激酶抑制剂
TW202214631A (zh) 作為Akt激酶抑制劑的化合物
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
WO2023232135A1 (zh) Pde4b抑制剂及其用途
TW202322819A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
CN115594680A (zh) 一种tead抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination